Abstract
Hepatitis C virus (HCV) is one of the main drivers of hepatic inflammation worldwide, being a leading contributor to the occurrence of liver cirrhosis, hepatocarcinoma, and consequently liver transplants. Although there is no vaccine available against HCV, advances in direct-acting antiviral therapy have presented above-average results in terms of viral inhibition, despite the fact that t…